参考文献/References:
[1] Fernandes-Rosa FL,Boulkroun S,Zennaro MC. genetic and genomic mechanisms of primary aldosteronism[J].Trends Mol Med,2020,26(9):819-832.DOI:10.1016/j.molmed.2020.05.005.
[2] Aglony M,Martínez-Aguayo A,Carvajal CA,et al. Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population:clinical and biochemical presentation[J].Hypertension,2011,57(6):1117-1121.DOI:10.1161/hypertensionaha.110.168740.
[3] Lifton RP,Dluhy RG,Powers M,et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase[J].Nat Genet,1992,2(1):66-74.DOI:10.1038/ng0992-66.
[4] Perez-Rivas LG,Williams TA,Reincke M. Inherited forms of primary hyperaldosteronism:new genes,new phenotypes and proposition of a new classification[J].Exp Clin Endocrinol Diabetes,2019,127(2-03):93-99.DOI:10.1055/a-0713-0629.
[5] Scholl UI,Stölting G,Schewe J,et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type Ⅱ[J].Nat Genet,2018,50(3):349-354.DOI:10.1038/s41588-018-0048-5.
[6] Fernandes-Rosa FL,Daniil G,Orozco IJ,et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism[J].Nat Genet,2018,50(3):355-361.DOI:10.1038/s41588-018-0053-8.
[7] Scholl UI,Stölting G,Nelson-Williams C,et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism[J].Elife,2015,4:e06315.DOI:10.7554/eLife.06315.
[8] Seidel E,Schewe J,Scholl UI. Genetic causes of primary aldosteronism[J].Exp Mol Med,2019,51(11):1-12.DOI:10.1038/s12276-019-0337-9.
[9] Fernandes-Rosa FL,Williams TA,Riester A,et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma[J].Hypertension,2014,64(2):354-361.DOI:10.1161/hypertensionaha.114.03419.
[10] Nanba K,Omata K,Else T,et al. Targeted molecular characterization of aldosterone-producing adenomas in white americans[J].J Clin Endocrinol Metab,2018,103(10):3869-3876.DOI:10.1210/jc.2018-01004.
[11] Okamura T,Nakajima Y,Katano-Toki A,et al. Characteristics of Japanese aldosterone-producing adenomas with KCNJ5 mutations[J].Endocr J,2017,64(1):39-47.DOI:10.1507/endocrj.EJ16-0243.
[12] Kitamoto T,Omura M,Suematsu S,et al. KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma[J].J Hypertens,2018,36(3):619-627.DOI:10.1097/HJH.0000000000001578.
[13] Zheng F,Zhu L,Nie A,et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma[J].Hypertension,2015,65(3):622-628.DOI:10.1161/hypertensionaha.114.03346.
[14] Nanba K,Omata K,Gomez-Sanchez CE,et al. Genetic characteristics of aldosterone-producing adenomas in blacks[J].Hypertension,2019,73(4):885-892.DOI:10.1161/HYPERTENSIONAHA.118.12070.
[15] Rhayem Y,Perez-Rivas LG,Dietz A,et al. PRKACA somatic mutations are rare findings in aldosterone-producing adenomas[J].J Clin Endocrinol Metab,2016,101(8):3010-3017.DOI:10.1210/jc.2016-1700.
[16] Ono Y,Yamazaki Y,Omata K,et al. Histological characterization of aldosterone-producing adrenocortical adenomas with different somatic mutations[J].J Clin Endocrinol Metab,2020,105(3):e282-e289.DOI:10.1210/clinem/dgz235.
[17] De Sousa K,Boulkroun S,Baron S,et al. Genetic,cellular,and molecular heterogeneity in adrenals with aldosterone-producing adenoma[J].Hypertension,2020,75(4):1034-1044.DOI:10.1161/HYPERTENSIONAHA.119.14177.
[18] Lenzini L,Rossitto G,Maiolino G,et al. A meta-analysis of somatic KCNJ5 K(+)channel mutations in 1636 patients with an aldosterone-producing adenoma[J].J Clin Endocrinol Metab,2015,100(8):E1089-E1095.DOI:10.1210/jc.2015-2149.
[19] Gomez-Sanchez CE,Gomez-Sanchez EP,Nishimoto K. Immunohistochemistry of the human adrenal CYP11B2 in normal individuals and in patients with primary aldosteronism[J].Horm Metab Res,2020,52(6):421-426.DOI:10.1055/a-1139-2079.
[20] Omata K,Anand SK,Hovelson DH,et al. Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals[J].J Endocr Soc,2017,1(7):787-799.DOI:10.1210/js.2017-00134.
相似文献/References:
[1]高海静,温俊平.肾上腺醛固酮腺瘤术后临床转归的影响因素[J].国际内分泌代谢杂志,2016,36(01):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
Gao Haijing,Wen Junping..Influence factors of postoperative clinical outcomes for patients with adrenal aldosteronoma[J].International Journal of Endocrinology and Metabolism,2016,36(02):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
[2]罗凯明 蒋晓红 华飞.糖尿病对肿瘤发生的影响及机制[J].国际内分泌代谢杂志,2020,40(02):125.[doi:10.3760/cma.j.issn.1673-4157.2020.02.013]
Luo Kaiming,Jiang Xiaohong,Hua Fei.Effects and mechanisms of diabetes on tumorigenesis[J].International Journal of Endocrinology and Metabolism,2020,40(02):125.[doi:10.3760/cma.j.issn.1673-4157.2020.02.013]
[3]杨小颖 唐露霖 尚文斌.表观遗传修饰在自身免疫性甲状腺疾病发病中的作用[J].国际内分泌代谢杂志,2020,40(03):169.[doi:10.3760/cma.j.issn.1673-4157.2020.03.006]
Yang Xiao-ying,Tang Lulin,Shang Wenbin.The role of epigenetic modification in the pathogenesis of autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(02):169.[doi:10.3760/cma.j.issn.1673-4157.2020.03.006]
[4]钟珊,宋筱筱,徐小红.原发性醛固酮增多症分型诊断研究进展[J].国际内分泌代谢杂志,2020,40(05):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
Zhong Shan,Song Xiaoxiao,Xu Xiaohong.Research progress of subtype diagnosis in primary hyperaldosteronism[J].International Journal of Endocrinology and Metabolism,2020,40(02):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
[5]郑爱琳,宋颖,罗蓉,等.关于原发性醛固酮增多症诊治的常见误区[J].国际内分泌代谢杂志,2021,41(02):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
Zheng Ailin,Song Ying,Luo Rong,et al.Misunderstandings in the diagnosis and treatment of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(02):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
[6]马晓森,童安莉.嗜铬细胞瘤分子病因学研究进展[J].国际内分泌代谢杂志,2021,41(02):82.[doi:10.3760/cma.j.cn121383-20200630-06087]
Ma Xiaosen,Tong Anli..Research progress on the molecular etiology of pheochromocytoma[J].International Journal of Endocrinology and Metabolism,2021,41(02):82.[doi:10.3760/cma.j.cn121383-20200630-06087]
[7]戴媛,吴文君.T2DM骨骼肌病变的研究进展[J].国际内分泌代谢杂志,2021,41(04):352.[doi:10.3760/cma.j.cn121383-20200622-06061]
Dai yuan,Wu Wenjun..Research progress on the type 2 diabetic myopathy[J].International Journal of Endocrinology and Metabolism,2021,41(02):352.[doi:10.3760/cma.j.cn121383-20200622-06061]
[8]郭富饶,李启富,徐智新.血浆肾素测定方法的新进展及临床意义[J].国际内分泌代谢杂志,2021,41(06):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
Guo Furao,Li Qifu,Xu Zhixin..Advances and clinical value of plasma renin measurement[J].International Journal of Endocrinology and Metabolism,2021,41(02):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
[9]许媛 许岚 张丽华 李启富 杨淑敏.中国原发性醛固酮增多症诊断现状调查研究[J].国际内分泌代谢杂志,2022,42(04):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
Xu Yuan,Xu Lan,Zhang Lihua,et al.Investigation on current status of diagnosis of primary aldosteronism in China[J].International Journal of Endocrinology and Metabolism,2022,42(02):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
[10]杨成艳,李新培,马晓庆.孤立性促肾上腺皮质激素缺乏症的诊疗进展[J].国际内分泌代谢杂志,2023,43(03):211.[doi:10.3760/cma.j.cn121383-20220420-04050]
Yang Chengyan,Li Xinpei,Ma Xiaoqing..The progress of diagnosis and treatment of isolated adrenocorticotropic hormone deficiency[J].International Journal of Endocrinology and Metabolism,2023,43(02):211.[doi:10.3760/cma.j.cn121383-20220420-04050]